314 related articles for article (PubMed ID: 35598254)
1. Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases.
Schlam I; Gatti-Mays ME
Oncologist; 2022 Jul; 27(7):538-547. PubMed ID: 35598254
[TBL] [Abstract][Full Text] [Related]
2. Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.
Yamashita D; Minata M; Ibrahim AN; Yamaguchi S; Coviello V; Bernstock JD; Harada S; Cerione RA; Tannous BA; La Motta C; Nakano I
Mol Cancer Ther; 2020 May; 19(5):1134-1147. PubMed ID: 32127468
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development.
Saraf A; Grubb CS; Hwang ME; Tai CH; Wu CC; Jani A; Lapa ME; Andrews JIS; Vanderkelen S; Isaacson SR; Sonabend AM; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Cheng SK; Connolly EP; Wang TJC
J Neurooncol; 2017 Sep; 134(2):453-463. PubMed ID: 28674973
[TBL] [Abstract][Full Text] [Related]
4. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
Shah N; Mohammad AS; Saralkar P; Sprowls SA; Vickers SD; John D; Tallman RM; Lucke-Wold BP; Jarrell KE; Pinti M; Nolan RL; Lockman PR
Pharmacol Res; 2018 Jun; 132():47-68. PubMed ID: 29604436
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment.
Morikawa A; Li J; Ulintz P; Cheng X; Apfel A; Robinson D; Hopkins A; Kumar-Sinha C; Wu YM; Serhan H; Verbal K; Thomas D; Hayes DF; Chinnaiyan AM; Baladandayuthapani V; Heth J; Soellner MB; Merajver SD; Merrill N
Cancer Res Commun; 2023 Jun; 3(6):1093-1103. PubMed ID: 37377606
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
7. Current challenges in the management of breast cancer brain metastases.
O'Sullivan CC; Davarpanah NN; Abraham J; Bates SE
Semin Oncol; 2017 Apr; 44(2):85-100. PubMed ID: 28923217
[TBL] [Abstract][Full Text] [Related]
8. Management of brain metastases in breast cancer: a review of current practices and emerging treatments.
Mills MN; Figura NB; Arrington JA; Yu HM; Etame AB; Vogelbaum MA; Soliman H; Czerniecki BJ; Forsyth PA; Han HS; Ahmed KA
Breast Cancer Res Treat; 2020 Apr; 180(2):279-300. PubMed ID: 32030570
[TBL] [Abstract][Full Text] [Related]
9. Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.
Sambade MJ; Prince G; Deal AM; Trembath D; McKee M; Garrett A; Keith K; Ramirez J; Midkiff B; Blackwell K; Sammons S; Leone JP; Brufsky A; Morikawa A; Brogi E; Seidman A; Ewend M; Carey LA; Moschos SJ; Hamilton RL; Vincent B; Anders C
Breast Cancer Res Treat; 2019 Jul; 176(2):321-328. PubMed ID: 31016641
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
11. Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE; Tolaney SM
J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the management of brain metastases from hormone receptor positive breast cancer.
Jusino S; Fadul CE; Dillon P
J Neurooncol; 2023 Mar; 162(1):45-57. PubMed ID: 36884200
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH
Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210
[TBL] [Abstract][Full Text] [Related]
14. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
15. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
16. Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer.
Jarroudi OA; Bairi KE; Curigliano G; Afqir S
Cancer Treat Res; 2023; 188():29-62. PubMed ID: 38175341
[TBL] [Abstract][Full Text] [Related]
17. New insights and emerging therapies for breast cancer brain metastases.
Lim E; Lin NU
Oncology (Williston Park); 2012 Jul; 26(7):652-9, 663. PubMed ID: 22888567
[TBL] [Abstract][Full Text] [Related]
18. Tumor lineage-specific immune response in brain metastatic disease: opportunities for targeted immunotherapy regimen?
Najjary S; Kros JM; de Koning W; Vadgama D; Lila K; Wolf J; Mustafa DAM
Acta Neuropathol Commun; 2023 Apr; 11(1):64. PubMed ID: 37061716
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape.
Uliano J; Nicolò E; Corvaja C; Taurelli Salimbeni B; Trapani D; Curigliano G
Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1399-1413. PubMed ID: 36317756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
